Home
Research
Submit Article
News
Sectors
Advertise
Premium
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial
About Us
About Us
Editorial Staff
Terms and Conditions
Privacy Policy
Contact Us
iStock Rating
D
Details...
Enter Symbol
Amarin Corporation PLC (NASDAQ: AMRN)
Sector: Medical
Current Price :
$6.47
52 Week Low
$6.39
52 Week High
$15.46
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Shares Outstanding:
150M
Market Cap:
$1.02B
Avg Volume:
3456464
P/E Ratio:
-0.010
PEG Ratio:
-0.010
Split:
On 1/18/2008 amrn split by factor of 0.100
Opinion and Analysis
Stocks End Mixed Amid 'Cliff' Talks, Data; Apple (AAPL) Retreats
Dec 07, 2012 04:30 PM |
AAPL
,
AIG
,
AMRN
,
CMTL
,
ESL
,
GEO
Futures Rise After Jobs Report; Netflix (NFLX) Eyed
Dec 07, 2012 09:16 AM |
AMRN
,
COO
,
MCD
,
MHP
,
NFLX
Tough, Volatile Session Ends Lower
Nov 27, 2012 10:19 PM |
AAPL
,
ACAD
,
AMRN
,
AMZN
,
APKT
,
APOG
More Articles on AMRN..
Press Releases
Amarin Informed by FDA of October 16th Advisory Committee Date in Connection With Supplemental New Drug Application (sNDA) for Vascepa(R) in the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
Jun 19, 2013 07:59 AM |
AMRN
Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
May 22, 2013 09:51 AM |
AMRN
Photo Release -- Amarin Reports First Quarter 2013 Financial Results and Provides Update on Operations
May 09, 2013 04:05 PM |
AMRN
More Press Releases on AMRN..
Sentiment Survey
Avg. Short Term
Avg. Long Term
Avg. Grade
More Details
Share Performance
Period
AMRN
Compare to S&P
YTD
-16.44 %
-26.74 %
4 Weeks
-5.32 %
-2.95 %
12 Weeks
-11.40 %
-15.21 %
More...
Financial Ratios
Earnings Performance
EPS Growth in Last Quarter:
-41.94 %
EPS Growth in Last Year:
-214.29 %
Sales Growth in Last Quarter:
-0.01 %
Sales Growth in Last Quarter:
-0.01 %
More...
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##